佳礼资讯网

 找回密码
 注册

ADVERTISEMENT

楼主: icy97

【MGRC 0155 交流专区】基因组学资源

[复制链接]
 楼主| 发表于 10-10-2021 09:34 AM | 显示全部楼层
Notice of Person Ceasing (Section 139 of CA 2016)
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD
Particulars of Substantial Securities Holder
Name
MADAM LIW CHAI YUK
Nationality/Country of incorporation
Malaysia
Descriptions (Class)
Ordinary Class
Name of registered holder
Liw Chai Yuk
Date of cessation
06 Oct 2021
No of securities disposed
4,750,000
Circumstances by reason of which a person ceases to be a substantial shareholder
Disposal of 4,750,000 shares via open market and ceased to be a Substantial Shareholder of the Company.
Nature of interest
Direct Interest
Date of notice
08 Oct 2021
Date notice received by Listed Issuer
08 Oct 2021

回复

使用道具 举报


ADVERTISEMENT

 楼主| 发表于 16-11-2021 07:52 AM | 显示全部楼层
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Date of change
01 Nov 2021
Name
MISS GRACE HOW PEI YEN
Age
41
Gender
Female
Nationality
Malaysia
Designation
Director
Directorate
Executive
Type of change
Resignation
Reason
Pre-occupation with both her mother and her son, thus she is not in a position to devote her time to the affairs of the Company.

回复

使用道具 举报

 楼主| 发表于 18-11-2021 07:55 AM | 显示全部楼层
Notice of Person Ceasing (Section 139 of CA 2016)
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD
Particulars of Substantial Securities Holder
Name
I CONCEPT GLOBAL GROWTH FUND
Address
89, Nexus Way, Camana Bay,Grand Cayman,
KY1-9009, Cayman Islands
Cayman Islands.
Company No.
BS-328056
Nationality/Country of incorporation
Cayman Islands
Descriptions (Class)
Ordinary Shares
Name of registered holder
Affin Hwang Nominees (Asing) Sdn Bhd Exempt an for Phillip Securities (Hong Kong) Ltd(for I Concept)
Address of registered holder
27th Floor, MenaraBoustead, 69 JalanRaja Chulan,50200 KualaLumpur, Malaysia.
Date of cessation
02 Nov 2021
No of securities disposed
4,688,000
Circumstances by reason of which a person ceases to be a substantial shareholder
Disposal of 2,088,000 shares and 2,600,000 shares on 1 November 2021 and 2 November 2021 respectively via open market and ceased to be a Substantial Shareholder of the Company.
Nature of interest
Direct Interest
Date of notice
03 Nov 2021
Date notice received by Listed Issuer
03 Nov 2021

回复

使用道具 举报

 楼主| 发表于 18-11-2021 07:56 AM | 显示全部楼层
Notice of Interest Sub. S-hldr (Section 137 of CA 2016)
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD
Particulars of Substantial Securities Holder
Name
PIXELVEST SDN BHD
Address
Emporis Soho, F-16-03, Block F,
Emporis Persiaran Surian Seksyen 3,
Kota Damansara, Taman Sains Selangor,
Petaling Jaya
47810 Selangor
Malaysia.
Company No.
202001018665 (1374985-D)
Nationality/Country of incorporation
Malaysia
Descriptions (Class)
Ordinary Shares
Name of registered holder
PIXELVEST SDN BHD
Address of registered holder
Emporis Soho, F-16-03, Block F, Emporis Persiaran Surian Seksyen 3, Kota Damansara, Taman Sains Selangor, 47810 Petaling Jaya, Selangor, Malaysia.
Date interest acquired & no of securities acquired
Date interest acquired
01 Nov 2021
No of securities
550,000
Circumstances by reason of which Securities Holder has interest
Acquisition of 550,000 shares in the open market and becoming a substantial shareholder of the Company.
Nature of interest
Direct Interest
Total no of securities after change
Direct (units)
6,680,000
Direct (%)
5.378
Indirect/deemed interest (units)
0
Indirect/deemed interest (%)
0
Date of notice
03 Nov 2021
Date notice received by Listed Issuer
03 Nov 2021


回复

使用道具 举报

 楼主| 发表于 13-2-2022 10:39 AM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2021
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30 Sep 2021
30 Sep 2020
30 Sep 2021
30 Sep 2020
$$'000
$$'000
$$'000
$$'000
1Revenue
9,316
87
9,316
87
2Profit/(loss) before tax
239
-833
239
-833
3Profit/(loss) for the period
239
-833
239
-833
4Profit/(loss) attributable to ordinary equity holders of the parent
239
-833
239
-833
5Basic earnings/(loss) per share (Subunit)
0.20
-0.80
0.20
-0.80
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
0.2421
0.1513

回复

使用道具 举报

 楼主| 发表于 13-2-2022 10:41 AM | 显示全部楼层
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Date of change
30 Nov 2021
Name
TAN SRI DATUK (DR) RAFIAH BINTI SALIM
Age
74
Gender
Female
Nationality
Malaysia
Designation
Chairman
Directorate
Independent and Non Executive
Type of change
Retirement
Qualifications
No
Qualifications
Major/Field of Study
Institute/University
Additional Information

Working experience and occupation
Family relationship with any director and/or major shareholder of the listed issuer
NIL
Any conflict of interests that he/she has with the listed issuer
NIL
Details of any interest in the securities of the listed issuer or its subsidiaries
Direct : 200,000 Ordinary Shares


回复

使用道具 举报

Follow Us
 楼主| 发表于 14-2-2022 10:17 AM | 显示全部楼层
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Date of change
30 Nov 2021
Name
MR CHEAH SEK HON
Age
46
Gender
Male
Nationality
Malaysia
Type of change
Resignation
Designation
Chief Financial Officer
Reason
Pursue other career opportunities




Date of change
30 Nov 2021
Name
MISS TEOH AI LING
Age
38
Gender
Female
Nationality
Malaysia
Type of change
Appointment
Designation
Others
Qualifications
No
Qualifications
Major/Field of Study
Institute/University
Additional Information
1
Professional Qualification
Accounting
Fellow Member of The Association of Chartered Certified Accountants
2014
2
Professional Qualification
Accounting
Member of The Association of Chartered Certified Accountants
2009
3
Professional Qualification
Accounting
The Association of Chartered Certified Accountants
2005 - 2007
4
Others
Commerce Financial Reporting (Advanced Diploma)
Tunku Abdul Rahman College
2003 - 2005
  
Working experience and occupation
Ms Teoh Ai Ling (Ms Teoh) has 15 years of work experience in the finance and accounting fields. The details of her work experience are as follow:-1.        Served as Financial Controller in public listed companies;2.        Was responsible for financial reporting to comply with MFRS, such as preparing quarterly reports to Bursa, reporting to the Board of Directors;3.        Ensured compliance of all legal requirements, such as general accounting principles/standards/Bursa listing requirements, Income Tax Act, etc.;4.        Liaised with auditors, bankers, tax agents and other relevant external business partners, and ensured tax computations for the Company; and5.        Reviewed financial work policies, processes and procedures to comply with the companys objectives. Monitored daily cash flow for operations requirements of the company and recommended necessary actions to the management.

回复

使用道具 举报

 楼主| 发表于 22-9-2022 08:50 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY)- LETTER OF INTENT WITH UNIVERSITI MALAYSIA SABAH AND RINANI GENOTEC SDN BHD FOR COLLABORATION ON RESEARCH AND DEVELOPMENT IN GENETICS, AND REGENERATIVE AND ALTERNATIVE MEDICINES.
For details of this announcement, kindly refer to the attachments.

This announcement is dated 21 September 2022.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3293448

回复

使用道具 举报


ADVERTISEMENT

 楼主| 发表于 24-9-2022 09:20 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY) - COLLABORATION AND SUPPLY AGREEMENT BETWEEN MGRC AND ACQUEST HEALTHCARE STEM CELL RESEARCH AND DEVELOPMENT CO., LTD.
For details of this announcement kindly refer to the attachment.

This announcement is dated 23 September 2022.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3293979

回复

使用道具 举报

 楼主| 发表于 24-9-2022 09:20 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY) (I)        STRATEGIC COOPERATION AGREEMENT (II)        SUPPLY AND COLLABORATION AGREEMENT BETWEEN MGRC AND SALUS HOLDINGS COMPANY LIMITED
For details of this announcement kindly refer to the attachment.

This announcement is dated 23 September 2022.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3293980

回复

使用道具 举报

 楼主| 发表于 24-9-2022 09:21 AM | 显示全部楼层
本帖最后由 icy97 于 24-9-2022 09:22 AM 编辑

Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY)- LETTER OF INTENT WITH SALUS HOLDINGS COMPANY LIMITED AND THE MARINE GROUP COMPANY LIMITED FOR THE PROPOSED COLLABORATION ON RESEARCH AND DEVELOPMENT IN GENETICS AND REGENERATIVE CELL THERAPIES
For details of this announcement kindly refer to the attachment.

This announcement is dated 23 September 2022.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3293981

回复

使用道具 举报

 楼主| 发表于 24-9-2022 09:21 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
Malaysian Genomics Grows Presence in Thailand
We are please to attach herewith the press release dated 23 September 2022.

This announcement is dated 23 September 2022.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3293982

回复

使用道具 举报

 楼主| 发表于 13-10-2022 09:27 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR "COMPANY")- COOPERATION IN THE FIELD OF MEDICAL RESEARCH
For details of this announcement, kindly refer to the attachments.

This announcement is dated 12 October 2022.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3298576

回复

使用道具 举报

 楼主| 发表于 8-9-2023 12:53 PM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY)- STRATEGIC COLLABORATION AGREEMENT WITH YAYASAN KANSER MALAYSIA
For details of this announcement, kindly refer to the attachments.

This announcement is dated 6 September 2023.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3383611

回复

使用道具 举报

 楼主| 发表于 12-9-2023 09:43 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY)- STRATEGIC COLLABORATION AGREEMENT WITH PERSATUAN PENTAS ANAK SENI MALAYSIA
For details of this announcement, kindly refer to the attachments.

This announcement is dated 11 September 2023.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3384421

回复

使用道具 举报

 楼主| 发表于 14-9-2023 05:49 AM | 显示全部楼层
本帖最后由 icy97 于 5-3-2024 05:08 PM 编辑

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Date of change
04 Mar 2024
Name
ENCIK MUHAMMAD BADRI BIN HUSSIN
Age
50
Gender
Male
Nationality
Malaysia
Type of change
Redesignation
Previous Position
Director
New Position
Chief Operating Officer
Directorate
Independent and Non Executive
Qualifications
No
Qualifications
Major/Field of Study
Institute/University
Additional Information
1
Masters
Business Administration
Universiti Malaysia Pahang
2
Degree
Bachelor of Accounting (Hons)
Universiti Utara Malaysia

Working experience and occupation
Encik Muhammad Badri Bin Hussin ("Encik Badri") was the Group CEO of a private entity, Integra Healthcare Technology Sdn Bhd since 1st February 2023. He graduated from Universiti Utara Malaysia (UUM) in 1996 with Bachelor in Accountancy (Hons) and subsequently obtained a Master of Business Administration (MBA) from Universiti Malaysia Pahang (UMP) in 2015. Encik Badri began his career as an auditor with PricewaterhouseCoopers for four years from 1997 to 2001. He subsequently joined a retail pharmaceutical company, PharmaCare Medicine Shoppe Sdn Bhd in 2001. He later joined KPJ Healthcare Group and served with KPJ Healthcare Berhad for twenty-one years. He started as an accountant at KPJ Ampang Puteri in 2002 and was subsequently appointed as General Manager for Hospital Penawar Pasir Gudang in 2004 and Puteri Specialist Hospital Johor Baharu in 2006. He was then assigned to be a Director to manage two hospitals in Indonesia namely Rumah Sakit Medika Permata Hijau Jakarta in 2006 and Rumah Sakit Medika Bumi Serpong Damai Tangerang in 2009. In 2012, he was appointed as a General Manager of former KPJ Kuantan Specialist Hospital and subsequently promoted as Chief Executive Officer. He was involved in the development, commissioning and opening of the new KPJ Pahang Specialist Hospital in 2016 and was appointed as its Chief Executive Officer. In 2017, he was appointed as Chief Executive Officer of KPJ Tawakkal KL. In 2020, he was appointed as Chief Executive Officer as well as Director of KPJ Ampang Puteri Specialist Hospital.
回复

使用道具 举报


ADVERTISEMENT

 楼主| 发表于 5-3-2024 04:39 PM | 显示全部楼层
本帖最后由 icy97 于 8-3-2024 02:16 AM 编辑

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Date of change
04 Mar 2024
Name
ENCIK MUHAMMAD BADRI BIN HUSSIN
Age
50
Gender
Male
Nationality
Malaysia
Type of change
Redesignation
Previous Position
Director
New Position
Chief Operating Officer
Directorate
Executive
Qualifications
No
Qualifications
Major/Field of Study
Institute/University
Additional Information
1
Masters
Business Administration
Universiti Malaysia Pahang
2
Degree
Bachelor of Accounting (Hons)
Universiti Utara Malaysia

Working experience and occupation
Encik Muhammad Badri Bin Hussin ("Encik Badri") was the Group CEO of a private entity, Integra Healthcare Technology Sdn Bhd since 1st February 2023. He graduated from Universiti Utara Malaysia (UUM) in 1996 with Bachelor in Accountancy (Hons) and subsequently obtained a Master of Business Administration (MBA) from Universiti Malaysia Pahang (UMP) in 2015. Encik Badri began his career as an auditor with PricewaterhouseCoopers for four years from 1997 to 2001. He subsequently joined a retail pharmaceutical company, PharmaCare Medicine Shoppe Sdn Bhd in 2001. He later joined KPJ Healthcare Group and served with KPJ Healthcare Berhad for twenty-one years. He started as an accountant at KPJ Ampang Puteri in 2002 and was subsequently appointed as General Manager for Hospital Penawar Pasir Gudang in 2004 and Puteri Specialist Hospital Johor Baharu in 2006. He was then assigned to be a Director to manage two hospitals in Indonesia namely Rumah Sakit Medika Permata Hijau Jakarta in 2006 and Rumah Sakit Medika Bumi Serpong Damai Tangerang in 2009. In 2012, he was appointed as a General Manager of former KPJ Kuantan Specialist Hospital and subsequently promoted as Chief Executive Officer. He was involved in the development, commissioning and opening of the new KPJ Pahang Specialist Hospital in 2016 and was appointed as its Chief Executive Officer. In 2017, he was appointed as Chief Executive Officer of KPJ Tawakkal KL. In 2020, he was appointed as Chief Executive Officer as well as Director of KPJ Ampang Puteri Specialist Hospital.
回复

使用道具 举报

 楼主| 发表于 14-3-2024 12:13 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD (MGRC OR COMPANY) - COLLABORATION AGREEMENT BETWEEN MGRC THERAPEUTICS SDN BHD AND UNIVERSITI SAINS MALAYSIA
For details of this announcement, kindly refer to the attachments.

This announcement is dated 13 March 2024.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3430198

回复

使用道具 举报

 楼主| 发表于 14-3-2024 08:41 PM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR "COMPANY") - COLLABORATION AGREEMENT BETWEEN MGRC THERAPEUTICS SDN BHD AND UNIVERSITI SAINS MALAYSIA
Further to the Company's announcement dated 13 March 2024 on the collaboration agreement entered into between MGRC Therapeutics Sdn Bhd, a wholly owned subsidiary of the Company, and Universiti Sains Malaysia, the Board of Directors of MGRC would like to announce that the estimated funds to be provided from internally generated funds of the Group for the Project are as follows:
  • Budget administrative for research materials and supplies and professional services for exploring the genetics of Penang Woman is RM50,000.00.
  • Budget administrative for research materials and supplies used in determining the age of the ancient Penang Woman Skeleton using the Accelerator Mass Spectrometry (“AMS”) dating technique is RM3,000.00.

This announcement is dated 14 March 2024.

回复

使用道具 举报

 楼主| 发表于 19-4-2024 01:24 AM | 显示全部楼层
Type
Announcement
Subject
OTHERS
Description
MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR "COMPANY") - STRATEGIC COLLABORATION AGREEMENT BETWEEN MGRC HEALTHCARE SDN BHD AND DE CELL BERHAD
For details of this announcement, kindly refer to the attachments.

This announcement is dated 17 April 2024.
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3438524

回复

使用道具 举报

您需要登录后才可以回帖 登录 | 注册

本版积分规则

 

ADVERTISEMENT



ADVERTISEMENT



ADVERTISEMENT

ADVERTISEMENT


版权所有 © 1996-2023 Cari Internet Sdn Bhd (483575-W)|IPSERVERONE 提供云主机|广告刊登|关于我们|私隐权|免控|投诉|联络|脸书|佳礼资讯网

GMT+8, 12-12-2024 01:43 PM , Processed in 0.122914 second(s), 21 queries , Gzip On.

Powered by Discuz! X3.4

Copyright © 2001-2021, Tencent Cloud.

快速回复 返回顶部 返回列表